Organon Acquires Dermavant Sciences (VTAMA tapinarof cream, 1%)

NovaBay Pharmaceuticals Acquires DERMAdoctor

September 28, 2021

Consumer Products

NovaBay Pharmaceuticals, Inc. has entered into a definitive agreement to acquire DERMAdoctor, LLC for $15.0 million ( $12.0 million cash at closing plus up to $3.0 million in earnouts). The deal brings DERMAdoctor's ~30-product skincare portfolio and its 13-person team (co-founders Audrey and Jeff Kunin to remain) into NovaBay's commercial platform to expand its presence in the U.S. beauty market and capture revenue and operating synergies.

Roche Buys Telavant Holdings (Roivant/Pfizer) for $7.1B+

October 26, 2023

Healthcare Services

Roche entered into a definitive agreement to acquire Telavant Holdings, a company jointly owned by Roivant and Pfizer, for an upfront purchase price of $7.1 billion plus a near-term $150 million milestone payment. The deal gives Roche full rights to further develop, manufacture, and commercialize Telavant’s TL1A-directed antibody RVT-3101 in the US and Japan, with Pfizer retaining commercialization rights outside those territories.

Organon Acquires U.S. Rights to TOFIDENCE (tocilizumab-bavi) from Biogen

April 1, 2025

Pharmaceuticals

Organon has acquired regulatory and commercial rights in the United States for TOFIDENCE (tocilizumab-bavi), a biosimilar to Actemra, from Biogen. The deal includes an upfront payment to Biogen and Organon will assume tiered royalty and milestone obligations while Bio‑Thera Solutions will retain manufacturing rights for the U.S. market.

DermBiont Acquires SeylanMED to Expand Dermatology Pipeline

October 21, 2020

Biotechnology

DermBiont, a Boston-based clinical-stage precision dermatology company, has acquired SeylanMED, adding a targeted topical AKT inhibitor gel candidate for seborrheic keratosis to its pipeline. The acquisition expands DermBiont's therapeutic modalities and accelerates its objective to develop targeted topical treatments and live bacterial therapeutics for skin diseases.

Versant Diagnostics Acquires Cutaneous Pathology, P.A.

August 20, 2024

Healthcare Services

Versant Diagnostics, an independent physician services company based in Grapevine, Texas, has acquired Cutaneous Pathology, P.A., a dermatopathology practice in Winston-Salem, North Carolina. As part of the transaction, internationally recognized dermatopathologist Dr. Omar P. Sangueza has joined Versant to expand its national network of dermatopathology specialists.

Incyte to Acquire Villaris Therapeutics and Auremolimab (VM6)

October 3, 2022

Pharmaceuticals

Incyte has entered into an agreement to acquire Villaris Therapeutics, a Medicxi-backed biopharmaceutical focused on vitiligo. Incyte will pay $70 million upfront and provide potential additional milestone payments of up to $1.36 billion for auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody.